# A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

> **NCT07489196** · PHASE2 · NOT_YET_RECRUITING · sponsor: **CorrectSequence Therapeutics Co., Ltd** · enrollment: 20 (estimated)

## Conditions studied

- β-thalassemia Major

## Interventions

- **GENETIC:** CS-101 injection

## Key facts

- **NCT ID:** NCT07489196
- **Lead sponsor:** CorrectSequence Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-05
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07489196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07489196, "A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07489196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*